Put companies on watchlist
Fresenius SE & Co. KGaA
ISIN: DE0005785604
WKN: 578560
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Fresenius SE & Co. KGaA · ISIN: DE0005785604 · EQS - adhoc news (14 News)
Country: Germany · Primary market: Germany · EQS NID: 1505587
05 December 2022 11:40PM

Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company


EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Personnel
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company

05-Dec-2022 / 23:40 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company

Today, the Supervisory Board of Fresenius Medical Care Management AG, the General Partner of Fresenius Medical Care AG & Co. KGaA, has unanimously appointed Helen Giza as CEO of the Management Board with effect as of 6 December 2022. Helen Giza continues to serve as Chief Financial Officer of Fresenius Medical Care until further notice. Her predecessor, Dr. Carla Kriwet is leaving the company at her own request and by mutual agreement due to strategic differences.

As CEO of Fresenius Medical Care, Helen Giza will also join the Management Board of Fresenius Management SE. Dr. Carla Kriwet will leave the Management Board of Fresenius Management SE.

Fresenius SE & Co. KGaA, 
represented by Fresenius Management SE, 
The Management Board

Bad Homburg v.d.H., December 5, 2022

----------------------------------------
Contact:
Markus Georgi
Senior Vice President Investor Relations & Sustainability
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com
----------------------------------------

End of Note
 

05-Dec-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange
EQS News ID: 1505587

 
End of Announcement EQS News Service

1505587  05-Dec-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1505587&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Fresenius SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.